Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Discovering drugs that efficiently treat brain diseases has been challenging. Genetic variants that modulate the expression of potential drug targets can be utilized to assess the efficacy of therapeutic interventions. We therefore employed Mendelian Randomization (MR) on gene expression measured in brain tissue to identify drug targets involved in neurological and psychiatric diseases. We conducted a two-sample MR using cis-acting brain-derived expression quantitative trait loci (eQTLs) from the Accelerating Medicines Partnership for Alzheimer’s Disease consortium (AMP-AD) and the CommonMind Consortium (CMC) meta-analysis study (n = 1,286) as genetic instruments to predict the effects of 7,137 genes on 12 neurological and psychiatric disorders. We conducted Bayesian colocalization analysis on the top MR findings (using P<6x10-7 as evidence threshold, Bonferroni-corrected for 80,557 MR tests) to confirm sharing of the same causal variants between gene expression and trait in each genomic region. We then intersected the colocalized genes with known monogenic disease genes recorded in Online Mendelian Inheritance in Man (OMIM) and with genes annotated as drug targets in the Open Targets platform to identify promising drug targets. 80 eQTLs showed MR evidence of a causal effect, from which we prioritised 47 genes based on colocalization with the trait. We causally linked the expression of 23 genes with schizophrenia and a single gene each with anorexia, bipolar disorder and major depressive disorder within the psychiatric diseases and 9 genes with Alzheimer’s disease, 6 genes with Parkinson’s disease, 4 genes with multiple sclerosis and two genes with amyotrophic lateral sclerosis within the neurological diseases we tested. From these we identified five genes (ACE, GPNMB, KCNQ5, RERE and SUOX) as attractive drug targets that may warrant follow-up in functional studies and clinical trials, demonstrating the value of this study design for discovering drug targets in neuropsychiatric diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876 · cited 1×
“We further excluded participants of non-European ancestry [55].”
The MR-Base platform supports systematic causal inference across the human phenome
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018) · eLife · doi:10.7554/elife.34408 · Cited by 7,959
Self-citationMendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Self-citationMeta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 12×
“GWASs are increasingly becoming available on disease progression traits which can be used in future MR studies to confirm whether susceptibility loci are also involved in disease progression and can be targeted by drugs to slow this process.”
InfluentialSelf-citationGiambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004383 · Cited by 4,261
Genetic effects on gene expression across human tissues
GTEx Consortium (2017) · Nature · doi:10.1038/nature24277 · Cited by 4,036
LocusZoom: regional visualization of genome-wide association scan results
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., Boehnke, M., Abecasis, G. R., & Willer, C. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq419 · Cited by 2,707 · cited 1×
“org) [60] using 1000 Genomes EUR reference panel to compute the LD relative to the Wald ratio estimate for the gene with the lowest p-value in the region.”
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697 · cited 1×
“The 5 neurological traits included: Alzheimer’s disease, amyotrophic lateral sclerosis [51], frontotemporal dementia [52], multiple sclerosis [53], and Parkinson’s disease.”
Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis
Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M. J., Deelen, P., Zeng, B., Kirsten, H., Saha, A., Kreuzhuber, R., Kasela, S., et al. (2018) · doi:10.1101/447367 · Cited by 2,607
Self-citationOrienting the causal relationship between imprecisely measured traits using GWAS summary data.
Hemani, G., Tilling, K., & Davey Smith, G. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007081 · Cited by 2,607 · cited 1×
“Directionality can be determined using either bi-directional MR [64] or Steiger filtering [65,66].”
Self-citation
Cited by
Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A., Wallace, C., & Burgess, S. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.04.001 · Cited by 532
Bai, X., & Bian, Z. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.842288 · Cited by 66
Yang, C., Fagan, A. M., Perrin, R. J., Rhinn, H., Harari, O., & Cruchaga, C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01140-9 · Cited by 53
Cary, G. A., Wiley, J. C., Gockley, J., Keegan, S., Amirtha Ganesh, S. S., Heath, L., Butler, R. R., Mangravite, L. M., Logsdon, B. A., Longo, F. M., et al. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12461 · Cited by 49
Self-citation
Metadata
- Authors
- Baird, D. A., Liu, J. Z., Zheng, J., Sieberts, S. K., Perumal, T., Elsworth, B., Richardson, T. G., Chen, C.-Y., Carrasquillo, M. M., Allen, M., Reddy, J. S., De Jager, P. L., Ertekin-Taner, N., Mangravite, L. M., Logsdon, B., Estrada, K., Haycock, P. C., Hemani, G., Runz, H., Smith, G. D., Gaunt, T. R., & AMP-AD eQTL working group
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-01-08
- Volume
- 17
- Issue
- 1
- Pages
- e1009224
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W3119672187
- Cited by
- 83
- References
- 28
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. https://app.cochat.ai/papers/10.1371/journal.pgen.1009224
- The paper
- Baird, D. A., Liu, J. Z., Zheng, J., Sieberts, S. K., Perumal, T., Elsworth, B., Richardson, T. G., Chen, C.-Y., Carrasquillo, M. M., Allen, M., Reddy, J. S., De Jager, P. L., Ertekin-Taner, N., Mangravite, L. M., Logsdon, B., Estrada, K., Haycock, P. C., Hemani, G., Runz, H., . . . AMP-AD eQTL working group. (2021). Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1009224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.